{"id":25012,"date":"2025-06-06T14:30:52","date_gmt":"2025-06-06T07:30:52","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=25012"},"modified":"2025-06-06T14:30:52","modified_gmt":"2025-06-06T07:30:52","slug":"bioseedin-innovation-partnering-conference-2025-spotlight-on-chinas-biopharma-trailblazers-and-global-collaboration","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=25012","title":{"rendered":"BIOSeedin Innovation Partnering Conference 2025: Spotlight on China’s Biopharma Trailblazers and Global Collaboration"},"content":{"rendered":"

NEWARK, Del.<\/span>, June 6, 2025 \/PRNewswire\/ —<\/span><\/p>\n

China’s<\/span> influential innovative drug asset cooperation platform<\/span><\/b><\/p>\n

BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSeedin, BIOS has attracted cutting-edge biotech startups and top investment firms globally. It serves as a crucial platform for fostering collaboration between China’s<\/span> biopharma sector and global markets, facilitating partnerships, therapeutic asset licensing, and investment networking.<\/p>\n

The 5th annual BIOSeedin Innovation Partnering Conference solidified its role as a nexus for global biopharma innovation, attracting more than 2,000 registrants from 10 countries. Senior executives and investors dominated the audience, with 61.66% holding C-suite, BD, or investment roles. The event facilitated 7,275 meeting requests. Confirmed deals across oncology, rare diseases, and next-gen modalities. MNCs including Merck & Co., Pfizer and Bayer emerged as top targets, with key accounts receiving over 50 meeting requests each.<\/p>\n

Key Insights from BIOS Discussions<\/b><\/p>\n

Dr. Yi Zhu<\/span>, Founder and CSO of Biokin Pharma, framed China<\/span> as a “translational research powerhouse” uniquely positioned to de-risk high-impact modalities. “Our cost-efficient clinical execution enables rapid validation of novel ADCs and gene-editing platforms,” he noted, citing Biokin’s Phase II PD-1xLAG-3 bispecific antibody as evidence of China’s<\/span> ability to advance complex biologics. His call for investors to prioritize high-risk, high-reward assets resonated across sessions, particularly as Chinese startups now contribute 38% of global ADC patents.<\/p>\n

John Zhu<\/span>, CEO of DualityBio, challenged conventional innovation metrics during a standing-room-only session. “True differentiation isn’t about target novelty but biomarker-driven clinical value,” he asserted, showcasing DualityBio’s tumor-activated ADC linker technology. His critique of “therapeutic crowding” aligned with investor interest in China’s<\/span> precision medicine pipelines, particularly in NSCLC and triple-negative breast cancer.<\/p>\n

Dr. Zhang Lianshan, EVP of Hengrui Pharma, grounded discussions in localization imperatives. “Globalization starts with domestic validation,” he emphasized, detailing Hengrui’s strategy to leverage China’s<\/span> 140 million cancer patient registry for accelerated oncology trials. His case study on a Claudin 18.2-targeted therapy\u2014now in global Phase III\u2014highlighted China’s<\/span> evolving role from fast follower to protocol co-designer.<\/p>\n

Jacky Jiang<\/span>, BD Head at CSPC Pharma, outlined a pragmatic blueprint for strategic asset curation. “Align R&D with unmet needs, technical strengths, and M&A agility,” he advised, referencing CSPC’s recent acquisition of a CRISPR-Cas12Max delivery platform. His prediction that non-viral gene therapies will dominate rare disease investments by 2026 drew vigorous investor follow-ups.<\/p>\n

40 companies gave roadshows and brought abundant assets<\/b><\/p>\n

The BIOSeedin 2025 roadshow spotlighted China’s<\/span> accelerating leadership in next-generation therapies, with 40% of showcased assets featuring breakthrough modalities like Phase II PD-1xLAG-3 bispecifics for NSCLC, preclinical Claudin 18.2xCD3 T-cell engagers, and tumor microenvironment-activated ADC linkers\u2014technologies where Chinese firms now hold 32% of global patents. Rare disease innovations included non-viral CRISPR-Cas12Max therapies for retinal disorders (90% primate model efficacy) and Duchenne MD gene therapies, while metabolic\/CNS advances featured dual GLP-1<\/span>\/GIP agonists outperforming competitors in weight loss trials and tau-targeting Alzheimer’s mAbs. With 50% of programs in Phase I\/II (including 10 breakthrough-designated assets) and two Phase III candidates nearing 2026 NDAs\u2014a bispecific NSCLC antibody leveraging China’s<\/span> genomic databases and a non-opioid TRPV1-ATP analgesic\u2014the portfolio underscores China’s<\/span> evolution from fast follower to global innovator, combining cost-efficient development with patient-centric therapeutic engineering.<\/p>\n

Building on this year’s success, BIOSeedin 2026 will expand its global footprint with dedicated tracks for European and North American attendees.<\/p>\n

As Dr. Zhu Yi<\/span> concluded, “China’s<\/span> biotech sector is not just catching up\u2014it’s redefining innovation. We invite global partners to join this journey, where collaboration transcends borders and accelerates patient-centric breakthroughs.”<\/p>\n

Join us next year to explore investment opportunities, forge transformative partnerships, and shape the future of biopharma innovation.<\/p>\n

www.bioseedin.com<\/a>
service@bioseedin.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

NEWARK, Del.<\/span>, June 6, 2025 \/PRNewswire\/ —<\/span><\/p>\n

China’s<\/span> influential innovative drug asset cooperation platform<\/span><\/b><\/p>\n

BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSeedin, BIOS has attracted cutting-edge biotech startups and top investment firms globally. It serves as a crucial platform for fostering collaboration between China’s<\/span> biopharma sector and global markets, facilitating partnerships, therapeutic asset licensing, and investment networking.<\/p>\n

The 5th annual BIOSeedin Innovation Partnering Conference solidified its role as a nexus for global biopharma innovation, attracting more than 2,000 registrants from 10 countries. Senior executives and investors dominated the audience, with 61.66% holding C-suite, BD, or investment roles. The event facilitated 7,275 meeting requests. Confirmed deals across oncology, rare diseases, and next-gen modalities. MNCs including Merck & Co., Pfizer and Bayer emerged as top targets, with key accounts receiving over 50 meeting requests each.<\/p>\n

Key Insights from BIOS Discussions<\/b><\/p>\n

Dr. Yi Zhu<\/span>, Founder and CSO of Biokin Pharma, framed China<\/span> as a “translational research powerhouse” uniquely positioned to de-risk high-impact modalities. “Our cost-efficient clinical execution enables rapid validation of novel ADCs and gene-editing platforms,” he noted, citing Biokin’s Phase II PD-1xLAG-3 bispecific antibody as evidence of China’s<\/span> ability to advance complex biologics. His call for investors to prioritize high-risk, high-reward assets resonated across sessions, particularly as Chinese startups now contribute 38% of global ADC patents.<\/p>\n

John Zhu<\/span>, CEO of DualityBio, challenged conventional innovation metrics during a standing-room-only session. “True differentiation isn’t about target novelty but biomarker-driven clinical value,” he asserted, showcasing DualityBio’s tumor-activated ADC linker technology. His critique of “therapeutic crowding” aligned with investor interest in China’s<\/span> precision medicine pipelines, particularly in NSCLC and triple-negative breast cancer.<\/p>\n

Dr. Zhang Lianshan, EVP of Hengrui Pharma, grounded discussions in localization imperatives. “Globalization starts with domestic validation,” he emphasized, detailing Hengrui’s strategy to leverage China’s<\/span> 140 million cancer patient registry for accelerated oncology trials. His case study on a Claudin 18.2-targeted therapy\u2014now in global Phase III\u2014highlighted China’s<\/span> evolving role from fast follower to protocol co-designer.<\/p>\n

Jacky Jiang<\/span>, BD Head at CSPC Pharma, outlined a pragmatic blueprint for strategic asset curation. “Align R&D with unmet needs, technical strengths, and M&A agility,” he advised, referencing CSPC’s recent acquisition of a CRISPR-Cas12Max delivery platform. His prediction that non-viral gene therapies will dominate rare disease investments by 2026 drew vigorous investor follow-ups.<\/p>\n

40 companies gave roadshows and brought abundant assets<\/b><\/p>\n

The BIOSeedin 2025 roadshow spotlighted China’s<\/span> accelerating leadership in next-generation therapies, with 40% of showcased assets featuring breakthrough modalities like Phase II PD-1xLAG-3 bispecifics for NSCLC, preclinical Claudin 18.2xCD3 T-cell engagers, and tumor microenvironment-activated ADC linkers\u2014technologies where Chinese firms now hold 32% of global patents. Rare disease innovations included non-viral CRISPR-Cas12Max therapies for retinal disorders (90% primate model efficacy) and Duchenne MD gene therapies, while metabolic\/CNS advances featured dual GLP-1<\/span>\/GIP agonists outperforming competitors in weight loss trials and tau-targeting Alzheimer’s mAbs. With 50% of programs in Phase I\/II (including 10 breakthrough-designated assets) and two Phase III candidates nearing 2026 NDAs\u2014a bispecific NSCLC antibody leveraging China’s<\/span> genomic databases and a non-opioid TRPV1-ATP analgesic\u2014the portfolio underscores China’s<\/span> evolution from fast follower to global innovator, combining cost-efficient development with patient-centric therapeutic engineering.<\/p>\n

Building on this year’s success, BIOSeedin 2026 will expand its global footprint with dedicated tracks for European and North American attendees.<\/p>\n

As Dr. Zhu Yi<\/span> concluded, “China’s<\/span> biotech sector is not just catching up\u2014it’s redefining innovation. We invite global partners to join this journey, where collaboration transcends borders and accelerates patient-centric breakthroughs.”<\/p>\n

Join us next year to explore investment opportunities, forge transformative partnerships, and shape the future of biopharma innovation.<\/p>\n

www.bioseedin.com<\/a>
service@bioseedin.com<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-25012","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/25012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25012"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/25012\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}